Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Mar 09, 2021 10:25am
100 Views
Post# 32751861

RE:RE:Trogarzo on goodrx

RE:RE:Trogarzo on goodrx I agree they have ramped up the marketing as well, both drugs turn up on many well followed website much more frequently recently.
The little one off discount is a nice trade off for longer term profitability.
I believe the company really need to apply the same using well known platforms to market their R&D programs too.
Maybe they are holding back waiting for hard data but I don't think that's necessary, I loved Paul mentioning 12 billion revenues for cancer on fireside chat more of that please.
Wino115 wrote: Perhaps trying to gain the patients vs. Fostesemvir.  Need to be aggressive, as you say, given high compliance.  IV/IM is necessary to counter the pill element though. 

scarlet1967 wrote: More and more promotional programs for the drug.
With the drug having a great compliance rate these efforts are great, not sure who is behind it but the net effect is more patients who stay put.

https://www.goodrx.com/trogarzo




<< Previous
Bullboard Posts
Next >>